Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Sidana, Surbhi  [Clear All Filters]
Journal Article
Sidana S, M Sidiqi H, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, et al. 15 Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis. Am J Hematol. 2019.
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022.
Lemieux C, Johnston LJ, Lowsky R, Muffly LS, Craig JK, Shiraz P, Rezvani A, Frank MJ, Weng W-K, Meyer E, et al. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biol Blood Marrow Transplant. 2020.
Majhail NS, Chakraborty R, Shah GL, Hamilton BK, Scordo M, Sidana S. Patient-Reported Outcomes with Chimeric Antigen Receptor-T Cell Therapy: Challenges and Opportunities. Biol Blood Marrow Transplant. 2018.
Bader CS, Pavlova A, Lowsky R, Muffly L, Shiraz P, Arai S, Johnston LJ, Rezvani AR, Weng W-K, Miklos DB, et al. Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Adv. 2023.
Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng W-K, et al. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplant Cell Ther. 2021.
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, et al. Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2021.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.